Institution Directory

Clinical trials at University of Chicago Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1117

Shown on this page

Current sort

Live official records

Conditions: Cancer
Interventions: Antibody-Drug Conjugate; Drug
Lead sponsor: MBrace Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 17
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 13 more

Conditions: COVID-19
Interventions: Subjects with and without Long COVID; Biological
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bleeding, Clot Blood
Interventions: Aspirin, Warfarin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Houston, Texas

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: Michael J. Fox Foundation for Parkinson's Research; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Gainesville, Florida • Chicago, Illinois + 8 more

Conditions: Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Interventions: Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care; Combination Product · Other
Lead sponsor: Kari Nadeau, MD, PhD; Other
Eligibility: 1 Week to 12 Weeks
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 4
States / cities: Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more

Conditions: Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Interventions: HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine; Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 29
States / cities: Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more

Conditions: Asymptomatic
Interventions: Contrast-enhanced Magnetic Resonance Imaging, Digital Tomosynthesis Mammography, Quality-of-Life Assessment, Questionnaire Administration; Diagnostic Test · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 1,516 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 67
States / cities: Gilbert, Arizona • Pasadena, California • Denver, Colorado + 54 more

Conditions: Extensive-stage Small-cell Lung Cancer
Interventions: Ifinatamab Deruxtecan (I-DXd); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 16
States / cities: Springdale, Arkansas • Jacksonville, Florida • Tampa, Florida + 13 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Sernova Cell Pouch; Combination Product
Lead sponsor: Sernova Biotherapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Breast Cancer
Interventions: Enzalutamide, Mifepristone, TPC; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 9 more

Conditions: Ductal Breast Carcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Medullary Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Tubular Breast Carcinoma
Interventions: Radiation Therapy, Questionnaire Administration, Quality-of-Life Assessment, Laboratory Biomarker Analysis, Hypofractionated Radiation Therapy; Radiation · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 898 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2035
U.S. locations: 846
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 544 more

Conditions: Lung Cancer, Lung Carcinoma
Interventions: Low-dose Computed Tomography; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 80 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

About this University of Chicago Medicine institution page

What this page lists: ClinicalTrials.gov records that list University of Chicago Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Chicago Medicine

Filter and sort this campus

Live official records

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

Dysbiosis & Long COVID

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device

Black and African Americans Connections to Parkinson's Disease (BLAAC PD)

Seal, Stopping Eczema and Allergy Study

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

Lung Cancer Screening in High-risk Black Individuals

About this University of Chicago Medicine institution page